MTEX · XBRL financial data

Mannatech financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MTEX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	151,407	159,762	137,208	131,955	117,866	108,038
Cost of revenue	35,505	34,149	33,060	29,090	26,406	27,079
Gross profit	115,902	125,613	104,148	102,865	91,460	80,959
Research and development	800	1,200	1,000	800	700	800
Selling, general and administrative	—	—	—	—	41,722	39,658
General and administrative	27,845	29,427	27,470	48,613	41,722	—
Total operating expenses	111,411	116,564	104,553	103,829	90,031	81,385
Operating income (loss)	4,491	9,049	(405)	(964)	1,429	(426)
Interest expense	—	—	—	—	279	406
Other income (expense)	1,151	(223)	(162)	(170)	2,590	(2,057)
Income tax expense (benefit)	(536)	(950)	4,011	1,109	1,250	12,324
Net income (loss)	6,261	9,842	(4,490)	(2,239)	2,490	(15,213)
Earnings per share, basic USD per share	2.80	4.95	(2.35)	(1.20)	1.32	(8.00)
Earnings per share, diluted USD per share	2.77	4.71	(2.35)	(1.20)	1.32	(8.00)
Weighted average shares, basic thousands of shares	2,235	1,990	1,913	1,866	1,885	1,901
Weighted average shares, diluted thousands of shares	2,264	2,088	1,913	1,866	1,885	1,901

Fiscal years (MTEX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	22,207	24,185	13,777	7,731	11,396	6,185
Accounts receivable	186	90	218	91	19	1
Inventory	12,827	12,020	14,726	14,535	10,405	10,123
Prepaid and other current assets	2,962	2,888	2,389	1,774	1,755	1,701
Total current assets	42,477	42,838	34,953	27,664	26,121	20,576
Property and equipment, net	5,358	4,239	3,759	4,147	2,858	2,227
Right-of-use asset	6,900	4,700	4,600	3,300	2,094	3,292
Total assets	65,336	59,625	49,128	41,206	36,056	29,993
Accounts payable	4,797	3,969	4,361	4,010	2,070	2,410
Accrued liabilities	8,691	9,224	7,510	6,779	3,832	3,128
Total current liabilities	31,987	30,098	29,838	25,780	20,896	18,735
Lease liability, non-current	6,100	4,300	4,200	2,600	1,576	2,253
Total liabilities	39,364	35,213	34,952	30,722	27,442	35,216
Retained earnings (accumulated deficit)	2,213	7,708	1,686	(1,301)	1,189	(14,024)
Total stockholders' equity	25,972	24,412	14,176	10,484	8,614	(5,223)
Total liabilities and equity	65,336	59,625	49,128	41,206	36,056	29,993
Common shares outstanding (cover page) thousands of shares	2,069	2,069	1,874	1,860	1,901	1,930

Fiscal years (MTEX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	6,261	9,842	(4,490)	(2,239)	2,490	(15,213)
Stock-based compensation	334	260	337	278	291	379
Depreciation and amortization	1,990	1,719	1,627	1,628	1,534	1,092
Net cash from operating activities	6,030	10,774	(2,599)	(2,370)	2,261	(2,963)
Purchases of property and equipment	949	650	1,063	748	297	1,353
Net cash from investing activities	(947)	(650)	(1,063)	(747)	(285)	(1,353)
Share repurchases	5,933	5,052	1,982	176	0	—
Dividends paid	3,358	4,347	1,532	748	0	—
Net cash from financing activities	(9,919)	(9,289)	(4,331)	(1,903)	1,961	(561)
Net change in cash	(3,503)	(1,865)	(10,435)	(5,810)	3,128	(5,546)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.